Abstract
Background: There are no head-to-head randomized clinical trials comparing the efficacy and safety of insulin glargine 300 U/mL (Gla-300), a second-generation basal insulin analogue, with once-daily (OD) insulin premix.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
